e-learning
resources
ERJ
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Anti-IL5 and anti-IL5Ra therapy for clinically significant bronchiectasis with eosinophilic endotype: a case series
Jessica Rademacher, Stefanie Konwert, Jan Fuge, Sabine Dettmer, Tobias Welte, Felix C. Ringshausen
Source:
Eur Respir J, 55 (1) 1901333; 10.1183/13993003.01333-2019
Journal Issue:
January
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Jessica Rademacher, Stefanie Konwert, Jan Fuge, Sabine Dettmer, Tobias Welte, Felix C. Ringshausen. Anti-IL5 and anti-IL5Ra therapy for clinically significant bronchiectasis with eosinophilic endotype: a case series. Eur Respir J, 55 (1) 1901333; 10.1183/13993003.01333-2019
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
Predictive indexes in prolonged weaning of mechanical ventilation due to tracheostomy in patients with COVID-19 pneumonia
ERS statement for defining respiratory exacerbations in children and adolescents with bronchiectasis for clinical trials
Related content which might interest you:
Mepolizumab as a steroid-sparing agent for eosinophilic granulomatosis with poliangiitis: a case series
Source: International Congress 2019 – Asthma: outcomes of clinical trials and cohorts
Year: 2019
Mepolizumab efficacy in patients with severe eosinophilic asthma and bronchiectasis
Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma
Year: 2019
Characterisation of severe eosinophilic asthma patients who failed Mepolizumab therapy
Source: Virtual Congress 2020 – Monoclonal antibodies in asthma
Year: 2020
Response to benralizumab in severe eosinophilic asthma after intermediate-to-poor response to mepolizumab : a retrospective study.
Source: Virtual Congress 2020 – Monoclonal antibodies; randomised controlled trials and real-world studies in asthma
Year: 2020
Mepolizumab in real-life treatment of severe eosinophilic asthma
Source: Virtual Congress 2020 – Monoclonal antibodies in asthma
Year: 2020
Anti-interleukin 5 treatment in moderate to severe eosinophilic chronic obstructive pulmonary disease: a systematic review and meta-analysis
Source: International Congress 2019 – Advances in COPD pharmacology
Year: 2019
Asthma exacerbations and eosinophilic inflammation 6 months after treatment with mepolizumab in refractory eosinophilic asthma
Source: Annual Congress 2009 - Towards improving asthma control
Year: 2009
Rituximab in the treatment of refractory pulmonary sarcoidosis
Source: Eur Respir J 2014; 43: 1525-1528
Year: 2014
Inhaled antibiotics for stable non-cystic fibrosis bronchiectasis: a systematic review
Source: Eur Respir J 2014; 44: 382-393
Year: 2014
Idiopathic chronic eosinophilic pneumonia and asthma: how do they influence each other?
Source: Eur Respir J 2003; 22: 8-13
Year: 2003
Clinical response to mepolizumab in patients with severe eosinophilic asthma
Source: International Congress 2019 – Understanding, monitoring and targeting severe asthma
Year: 2019
Rapid Benralizumab effectiveness in patients with severe eosinophilic asthma and bronchiectasis
Source: Virtual Congress 2020 – Monoclonal antibodies in asthma
Year: 2020
Real-life treatment of severe eosinophilic asthma with mepolizumab
Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma
Year: 2019
Discontinuation of benralizumab in Canadian patients with severe eosinophilic asthma
Source: ERJ Open Res, 7 (4) 00465-2021; 10.1183/23120541.00465-2021
Year: 2021
Cyclophosphamide and low-dose prednisolone in idiopathic pulmonary fibrosis and fibrosing nonspecific interstitial pneumonia
Source: Eur Respir J 2005; 25: 528-533
Year: 2005
Novel treatment of eosinophilic bronchitis with allergic fungal sinusitis using mepolizumab
Source: International Congress 2017 – Evolution or revolution in the treatment of asthma and allergies
Year: 2017
Mepolizumab and the response to oral prednisolone in patients with severe eosinophilic asthma
Source: International Congress 2017 – Asthma management
Year: 2017
Infliximab: An effective rescue therapy in refractory extra-pulmonary sarcoidosis
Source: Annual Congress 2013 –Sarcoidosis and other granulomatosis
Year: 2013
Pulmonary bilateral infiltrates, eosinophilia, granulomatous skin lesions: clinical presentation in a particoular case of eosinophilic pneumonia toxocara canis IgG/IgM positive
Source: Eur Respir J 2002; 20: Suppl. 38, 315s
Year: 2002
Steroid sparing effect of anti-IgE antibody in allergic bronchopulmonary aspergillosis (ABPA) complicating cystic fibrosis
Source: Annual Congress 2013 –Cystic fibrosis: clinical problems, genetics and microbiology in children
Year: 2013
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept